IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
PR Newswire
CAESAREA, Israel, Aug. 13, 2026
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastasesCAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation. A new review cites ProSense®'s U.S. Food and Drug Administration ("FDA") marketing authorization, its inclusion in updated American Society of Breast Surgeons ("ASBrS") guidelines and encouraging outcomes from the five-year ICE3 clinical study (3.1% IBTR rate), while a second publication extends the clinical discussion of cryoablation to axillary lymph node metastases for both curative and palliative care.
